| In partnership with |  |
| & Prosperity Pub | Good day, 360! | Here are some of our top movers today. And want a LEG UP on timing your trades? One-and-done lifetime rates just opened to our members this NEW AI-trade timing indicator. Details HERE. | And… Market Masters is OPEN - the hottest trading room around 🔥. JW will be running down SPY and everything else from 9-11AM EST. Be there! | | FOCUS LIST🔎 | PRTG - Up over 150% in the pre-market after reporting promising preclinical results in Mesothelioma supporting first-in-human trial of PORT-7 | RNAZ - Up over 18% in pre after announcing initial dosing in fourth cohort of Phase 1 clinical trial with TTX-MC138 | KULR - Up over 18% in pre after reporting record financial results | | *sponsored by RYSE | Alexa, Ring, Nest, Apple, Roku… | | What do all of these smart home products have in common? | They are must-haves in homes everywhere, and now there's one more to add to the list… | Meet RYSE – the revolutionary way to automate your window blinds & shades. | And here's why investors are taking notice: | 📈 $10M+ in revenue and growing 200% year-over-year
🏢 In 127 Best Buy locations, with Home Depot launching in 2025
🔒 10+ patents protecting industry-leading technology | RYSE is on track to be the next big name in smart home automation—and you can invest at $1.90/share before their next wave of expansion. | Invest Today and earn up to 25% in bonus shares | Past performance is not indicative of future results. Email may contain forward-looking statements. See US Offering for details. Informational purposes only. | |
|
| | HOTLIST🔥 | PRTG - Up over 150% in the pre-market after reporting promising preclinical results in Mesothelioma supporting first-in-human trial of PORT-7 | Portage Biotech Inc. (PRTG) is a clinical stage immune-oncology company that engages in the research and develops pharmaceutical and biotechnology products. | In the after-hours yesterday, the company presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer Congress (ELCC), held in Paris, France March 26-29. | The new data demonstrate both single agent activity for PORT-7, and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. | Immunohistochemistry of the tumors revealed a significant infiltration of both CD3 and CD45 positive immune effector cells. Mesothelioma is an aggressive cancer with limited treatment options in need of novel approaches to overcome immune resistance. | To the company's knowledge, this is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage is making preparations to commence a first-in-human clinical trial with PORT-7. | Shares PRTG traded up over 150% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $13.50. Beyond that, $16 and $23 come into play. | Below $13.50, targets to the downside are $12.30, $11, $10, $9, $8, $6.70, $6 and $5. | | RNAZ - Up over 18% in pre after announcing initial dosing in fourth cohort of Phase 1 clinical trial with TTX-MC138 | TransCode Therapeutics Inc. (RNAZ) is a biopharmaceutical company that focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. | In the after-hours yesterday, the company announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. | Highlights include: | First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded enrollment No significant safety or dose limiting toxicities have been reported
| Shares of RNAZ traded up over 18% in the pre-market in reaction to the news. | | The $0.60 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $0.64, $0.70 and then the pre-market high at $0.7254. Beyond that, $0.7390, $0.75, $0.85 and $1 come into play. | Below $0.60, targets to the downside are $0.57, a gap fill at $0.52 with all-time lows below that. | | *together with ProsperityPub | Do You Want To Learn About High-Conviction Trade-Timing? | Then You Want To Learn About Graham's Newton Indicator. | Start at 02:00. Watch TODAY! | |
|
| | KULR - Up over 18% in pre after reporting record financial results | KULR Technology Group Inc. (KULR) through its subsidiary, KULR Technology Corporation, develops and commercializes thermal management technologies for electronics, batteries, and other components applications in the United States. | In the after-hours yesterday, the company reported record fourth quarter revenue and full-year 2024 financial results. | Highlights include: | Revenue increased by 44% to $3.37 million from the same quarterly period of the prior year. Operating loss decreased by 29% to $3.54 million from the same quarterly period of the prior year. The Company had $29.83 million in cash as of December 31, 2024, compared to $1.19 million as of December 31, 2023. In addition, the Company had $20.28 million of Bitcoin holdings as of December 31, 2024, compared to none as of December 31, 2023. Gross margin was 64% in the quarter ended December 31, 2024, compared to 29% in the same quarterly period of the prior year.
| Shares of KULR traded up over 18% in the pre-market in reaction to the news. | | The $1.67 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1.75, $1.82 and then the after-hours high at $1.85. Beyond that, $2 and $2.60 come into play. | Below $1.67, targets to the downside are $1.62, $1.55, $1.50 and then a gap fill at $1.46 with $1.15 below that. | | MARKET NEWS 📰 | | | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored content: RYSE has previously paid RagingBull.com (RB) thirty thousand dollars in cash and thirty thousand in shares to run advertisements enhancing public awareness of the company. RB is currently invested in this company. RB is currently an affiliate for RYSE and Prosperity Pub. RB is not responsible for any content hosted on affiliate's sites and it is the affiliate's responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don't spend any money on these products unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar